JP2000515368A5 - - Google Patents

Download PDF

Info

Publication number
JP2000515368A5
JP2000515368A5 JP1998505190A JP50519098A JP2000515368A5 JP 2000515368 A5 JP2000515368 A5 JP 2000515368A5 JP 1998505190 A JP1998505190 A JP 1998505190A JP 50519098 A JP50519098 A JP 50519098A JP 2000515368 A5 JP2000515368 A5 JP 2000515368A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP1998505190A
Other languages
English (en)
Japanese (ja)
Other versions
JP2000515368A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1997/009690 external-priority patent/WO1998001564A1/en
Publication of JP2000515368A publication Critical patent/JP2000515368A/ja
Publication of JP2000515368A5 publication Critical patent/JP2000515368A5/ja
Ceased legal-status Critical Current

Links

JP10505190A 1996-07-08 1997-07-03 Hivエンベロープポリペプチドおよびワクチン Ceased JP2000515368A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US67673796A 1996-07-08 1996-07-08
US08/676,737 1996-07-08
PCT/US1997/009690 WO1998001564A1 (en) 1996-07-08 1997-07-03 Hiv envelope polypeptides and vaccine

Publications (2)

Publication Number Publication Date
JP2000515368A JP2000515368A (ja) 2000-11-21
JP2000515368A5 true JP2000515368A5 (cg-RX-API-DMAC10.html) 2005-03-10

Family

ID=24715764

Family Applications (1)

Application Number Title Priority Date Filing Date
JP10505190A Ceased JP2000515368A (ja) 1996-07-08 1997-07-03 Hivエンベロープポリペプチドおよびワクチン

Country Status (13)

Country Link
US (1) US6090392A (cg-RX-API-DMAC10.html)
EP (1) EP0942988A1 (cg-RX-API-DMAC10.html)
JP (1) JP2000515368A (cg-RX-API-DMAC10.html)
AP (1) AP1282A (cg-RX-API-DMAC10.html)
AU (1) AU727107B2 (cg-RX-API-DMAC10.html)
CA (1) CA2259965A1 (cg-RX-API-DMAC10.html)
ID (1) ID17767A (cg-RX-API-DMAC10.html)
IL (2) IL127701A0 (cg-RX-API-DMAC10.html)
NZ (1) NZ333500A (cg-RX-API-DMAC10.html)
OA (1) OA10954A (cg-RX-API-DMAC10.html)
TW (1) TWI221846B (cg-RX-API-DMAC10.html)
WO (1) WO1998001564A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA975889B (cg-RX-API-DMAC10.html)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6562347B1 (en) 1998-03-12 2003-05-13 The United States Of America As Represented By The Department Of Health And Human Services Chemokine-tumor antigen fusion proteins as cancer vaccines
MXPA02007478A (es) 2000-02-04 2004-08-23 Univ Duke Vacuna contra el virus de inmunodeficiencia humana.
AU2001254567A1 (en) * 2000-05-02 2001-11-12 Simon Fraser University Polypeptides for use as a vaccine and/or treatment for hiv infection
AUPS065002A0 (en) 2002-02-20 2002-03-14 Immunaid Pty Ltd Strategy for retroviral immunotherapy
US20030228320A1 (en) * 2000-08-18 2003-12-11 Ashdown Martin Leonard Retroviral immunotherapy
WO2002022686A2 (en) 2000-09-15 2002-03-21 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, National Institutes Of Health, Office Of Technology Transfer Defensin-antigen fusion proteins
AU2001291050A1 (en) 2000-09-15 2002-03-26 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Viral chemokine-tumur antigen fusion proteins
WO2002064154A2 (en) * 2001-02-15 2002-08-22 The Government Of The United States Of America, Asrepresented By The Secretary Of The Department Of Health And Human Services Methods and compositions for inhibiting hiv-coreceptor interactions
AUPS054702A0 (en) * 2002-02-14 2002-03-07 Immunaid Pty Ltd Cancer therapy
AU2003298912B2 (en) * 2002-12-03 2011-06-02 Advanced Bioscience Laboratories, Inc. Polyvalent, primary HIV-1 glycoprotein DNA vaccines and vaccination methods
CA2528005A1 (en) * 2003-06-12 2004-12-23 Vaxgen, Inc. Hiv-1 envelope glycoproteins having unusual disulfide structure
US8076060B2 (en) * 2003-08-04 2011-12-13 Emil William Chynn Vaccination and immunotherapy as new therapeutic modalities in the treatment of glaucoma
US20070202119A1 (en) 2003-10-24 2007-08-30 Ashdown Martin L Method Of Therapy
ATE546733T1 (de) * 2004-09-08 2012-03-15 Immunaid Pty Ltd Therapiestrategie zur behandlung von autoimmunkrankheiten und degenerativen erkrankungen
WO2006031870A2 (en) * 2004-09-14 2006-03-23 Argos Therapeutics, Inc. Strain independent amplification of pathogens and vaccines thereto
CA2623197A1 (en) * 2005-09-22 2007-03-29 Prosci Incorporated Glycosylated polypeptides produced in yeast mutants and methods of use thereof
WO2009017743A2 (en) 2007-07-30 2009-02-05 Argos Therapeutics, Inc. Improved primers and probes for the amplification and detection of hiv gag, rev and nef polynucleotides
BRPI0914224A2 (pt) 2008-06-19 2019-09-24 Variation Biotechnologies Inc composições e métodos para tratar a gripe
HUE026456T2 (en) 2009-05-27 2016-05-30 Biotempus Ltd Methods of treating diseases
EP2451950B9 (en) 2009-07-06 2016-11-23 Variation Biotechnologies Inc. Methods for preparing vesicles and formulations produced therefrom
CA2803282C (en) 2009-07-06 2018-05-01 David E. Anderson Methods for preparing vesicles and formulations produced therefrom
EP2550362B1 (en) 2010-03-25 2017-01-04 Oregon Health&Science University Cmv glycoproteins and recombinant vectors
JP6119030B2 (ja) 2010-07-06 2017-04-26 ヴァリエーション バイオテクノロジーズ インコーポレイテッド インフルエンザを治療するための組成物及び方法
BR112013017939B1 (pt) 2011-01-13 2022-11-16 Variation Biotechnologies Inc Composição imunogênica liofilizada termoestável, uso e método para preparação da mesma
RS57397B8 (sr) 2011-06-10 2020-01-31 Univ Oregon Health & Science Cmv glikoproteini i rekombinantni vektori
US20130189754A1 (en) 2011-09-12 2013-07-25 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
CA2894442C (en) 2012-01-12 2020-01-21 Variation Biotechnologies Inc. Compositions and methods for treating viral infections
CA2894467A1 (en) 2012-01-27 2013-08-01 Variation Biotechnologies Inc. Methods for preparing thermostable compositions comprising a lipid component and thermolabile therapeutic agents
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
CN104955847A (zh) 2012-12-04 2015-09-30 马里兰州大学(巴尔的摩) HIV-1 Env结合抗体、融合蛋白及其使用方法
EP2848937A1 (en) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Methods of identifying novel HIV-1 immunogens
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
US9931394B2 (en) 2015-03-23 2018-04-03 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE138100T1 (de) * 1984-12-24 1996-06-15 Genentech Inc Fusionen von aids-verwandten polypeptiden
EP0279688B1 (en) * 1987-02-20 1997-04-16 Genentech, Inc. Methods and compositions for the use of HIV env polypeptides and antibodies thereto
IL89118A0 (en) * 1988-02-03 1989-08-15 Microgenesys Inc Vaccine containing polypeptides derived from the envelope gene of human immunodeficiency virus type 1
EP0339504A3 (en) * 1988-04-26 1990-09-12 The Du Pont Merck Pharmaceutical Company Human immunodeficiency virus (hiv) env-coded peptide capable of eliciting hiv-inhibiting antibodies in mammals
US5116740A (en) * 1988-08-16 1992-05-26 Akzo N.V. Method for producing native hiv gp160
CA2066607A1 (en) * 1989-09-22 1991-03-23 Thomas Kieber-Emmons Peptides associated with the cd4 binding region of gp120 and their methods of use
WO1991015238A1 (en) * 1990-04-03 1991-10-17 Genentech, Inc. Methods and compositions for vaccination against hiv
WO1991015512A2 (en) * 1990-04-03 1991-10-17 Genentech, Inc. Hiv envelope polypeptides
NZ267838A (en) * 1993-06-07 1997-12-19 Genentech Inc Preparation of an hiv gp 120 subunit vaccine involving determining a neutralising epitope in the v2 and/or c4 domains

Similar Documents

Publication Publication Date Title
JP2000502280A5 (cg-RX-API-DMAC10.html)
JP2000501771A5 (cg-RX-API-DMAC10.html)
JP2000501599A5 (cg-RX-API-DMAC10.html)
JP2000501018A5 (cg-RX-API-DMAC10.html)
JP2000500076A5 (cg-RX-API-DMAC10.html)
JP2000501324A5 (cg-RX-API-DMAC10.html)
JP2000500026A5 (cg-RX-API-DMAC10.html)
JP2000502472A5 (cg-RX-API-DMAC10.html)
JP2000501825A5 (cg-RX-API-DMAC10.html)
JP2000501338A5 (cg-RX-API-DMAC10.html)
JP2000500874A5 (cg-RX-API-DMAC10.html)
JP2000502425A5 (cg-RX-API-DMAC10.html)
JP2000502485A5 (cg-RX-API-DMAC10.html)
JP2000502568A5 (cg-RX-API-DMAC10.html)
JP2000501774A5 (cg-RX-API-DMAC10.html)
JP2000500912A5 (cg-RX-API-DMAC10.html)
JP2000502570A5 (cg-RX-API-DMAC10.html)
JP2000501876A5 (cg-RX-API-DMAC10.html)
JP2000501744A5 (cg-RX-API-DMAC10.html)
JP2000501229A5 (cg-RX-API-DMAC10.html)
JP2000502316A5 (cg-RX-API-DMAC10.html)
JP2000500857A5 (cg-RX-API-DMAC10.html)
JP2000502714A5 (cg-RX-API-DMAC10.html)
JP2000501569A5 (cg-RX-API-DMAC10.html)
JP2000500184A5 (cg-RX-API-DMAC10.html)